Skip Navigation
  Search Menu
Find an Expert

 

Challice Bonifant, M.D., Ph.D.

Photo of Dr. Challice Bonifant, M.D., Ph.D.

Assistant Professor of Oncology

Specializes in: Adolescents (12-18 years), Children (1-11 years), Infants (up to 1 year)

Expertise: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)

Research Interests: Immunotherapy of cancer; malignant hematology; engineered cellular immunotherapies for the treatment of Acute Myeloid Leukemia

Background

Dr. Bonifant is a pediatric oncologist on the blood and marrow transplantation team at the Sidney Kimmel Comprehensive Cancer Center and an Assistant Professor of Pediatric Oncology at the Johns Hopkins University School of Medicine. She is also a member of the Bloomberg-Kimmel Institute for Immunotherapy. Her clinical specialty is stem cell transplantation for high-risk leukemias.

Her research interests are in the areas of immunotherapy of cancer and malignant hematology. Currently, her research focuses on design and development of immune therapies as a treatment for poor-prognosis cancers, including development of engineered cellular immunotherapies for the treatment of Acute Myeloid Leukemia.

Dr. Bonifant is a graduate of Wake Forest University and Georgetown University. She completed her Pediatric and Hematology/Oncology training at Johns Hopkins and at Baylor College of Medicine. Prior to her appointment at Johns Hopkins, she was an Assistant Professor in Pediatrics-Hematology/Oncology at the University of Michigan.

...read more

Titles

  • Assistant Professor of Oncology
  • Assistant Professor of Pediatrics

Education

Degrees

  • MD, Georgetown University School of Medicine (2009)

Residencies

  • Johns Hopkins University School of Medicine / Pediatrics (2012)

Fellowships

  • Texas Children's Hospital / Pediatric Hematology-Oncology (2015)

Research & Publications

Selected Publications

Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Molecular Therapy: The Journal of the American Society of Gene Therapy. 2016; 24(9):1615-26.

Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Molecular Therapy Oncolytics. 2016; 3:16011.

Bonifant CL, Velasquez MP, Gottschalk S. Advances in immunotherapy for pediatric acute myeloid leukemia. Expert Opinion on Biological Therapy. 2018; 18(1):51-63.

Zolov SN, Rietberg SP, Bonifant CL. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells. Cytotherapy. 2018; 20(10):1259-1266.

Krawczyk E, Zolov SN, Huang K, Bonifant CL. T-cell Activity against AML Improved by Dual-Targeted T Cells Stimulated through T-cell and IL7 Receptors. Cancer Immunology Research. 2019; 7(4):683-692.

Patents

Combination CD123 and C-type Lectin Molecule 1 Targeted T cells for Acute Myeloid Leukemia (Co-Inventor)
Patent # US Provisional Patent Application No. 62/398,859, PCT application US2017/052989

Chimeric Antigen Receptor Comprised of CD123 Binding Domain and IL-7 Intracellular Signaling Domain
Patent # US Provisional Patent Application No. 16/644,900, PCT application No. 16/358,253

Chimeric Antigen Receptors Targeting Abnormal Glycobiology (Co-inventor)
Patent # US Provisional Application No. 62/802,001

Activities & Honors

Honors

  • 2018 Damon Runyon-Jake Wetchler Award for Pediatric Innovation, Damon Runyon Foundation-Jake Wetchler Foundation, 2018

Memberships

  • American Academy of Pediatrics, 2009
  • American Society of Hematology, 2012
  • American Society of Bone Marrow Transplantation, 2015

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile